董事
|
| |
年齡
|
| |
第一年
變成了 董事 |
| |
當前
公共 板 |
|
卡倫·L·肖斯(董事會主席) | | |
69
|
| |
2001
|
| |
1
|
|
安東尼·S·馬魯奇(首席執行官) | | |
61
|
| |
2008
|
| |
2
|
|
基思·L·布朗利 | | |
70
|
| |
2017
|
| |
1
|
|
謝麗爾·L·科恩 | | |
57
|
| |
2022
|
| |
2
|
|
赫伯特·J·康拉德 | | |
90
|
| |
2008
|
| |
2
|
|
麗塔·I·賈恩醫學博士 | | |
61
|
| |
2023
|
| |
3
|
|
詹姆斯·J·馬裏諾 | | |
73
|
| |
2017
|
| |
2
|
|
加里·A·尼爾醫學博士。 | | |
69
|
| |
2022
|
| |
2
|
|
小哈里·H·彭納 | | |
77
|
| |
1997
|
| |
1
|
|
屬性、經驗和技能
|
| |
凱倫·L·
鞋 |
| |
Anthony S.
馬魯奇 |
| |
基思·L·
布朗利 |
| |
謝麗爾·L·
科恩 |
| |
赫伯特·J·
康拉德 |
| |
麗塔·I
[br]Jain醫學博士 |
| |
James J.
馬裏諾 |
| |
Garry A.
尼爾,醫學博士。 |
| |
哈里·H
小彭納 |
| |||||||||||||||||||||||||||
行業經驗
|
| | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | |
高管/領導力經驗
|
| | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | |
科學研究/藥物開發
體驗 |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|
*
|
| | | | | | | | | |
|
*
|
| | | | | | | |
業務戰略/運營經驗
|
| | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | |
金融經驗
|
| | | | | | | | | | * | | | | | | * | | | | | | * | | | | | | | | | | | | | | | | | | * | | | | | | | | | | | | * | | |
商業體驗
|
| | | | | | | | | | | | | | | | | | | | | | * | | | | | | * | | | | | | | | | | | | | | | | | | | | | | | | | | |
併購經驗
|
| | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | |
上市公司董事會經驗
|
| | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | |
人口統計 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
種族/民族 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
亞洲人
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | * | | | | | | | | | | | | | | | | | | | | |
白色
|
| | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | | | | | | | * | | | | | | * | | | | | | * | | |
性別 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
女性
|
| | | | * | | | | | | | | | | | | | | | | | | * | | | | | | | | | | | | * | | | | | | | | | | | | | | | | | | | | |
男性
|
| | | | | | | | | | * | | | | | | * | | | | | | | | | | | | * | | | | | | | | | | | | * | | | | | | * | | | | | | * | | |
董事會規模:董事總數
|
| |
9
|
| |||||||||||||||||||||
性別:
|
| |
男性
|
| |
女性
|
| |
非二進制
|
| |
性別
未披露 |
| ||||||||||||
董事
|
| | | | 6 | | | | | | 3 | | | | | | — | | | | | | — | | |
人口統計背景: | | | | | | | | | | | | | | | | | | | | | | | | | |
非裔美國人或黑人
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
阿拉斯加原住民或原住民
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
亞洲人
|
| | | | — | | | | | | 1 | | | | | | — | | | | | | — | | |
西班牙裔或拉丁裔
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
夏威夷原住民或太平洋島民
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
白色
|
| | | | 6 | | | | | | 2 | | | | | | — | | | | | | — | | |
兩個或兩個以上種族或民族
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
LGBTQ+
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
未披露
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
個人姓名
|
| |
年齡
|
| |
職位和辦公室
|
|
安東尼·S·馬魯奇 | | |
61
|
| | 董事首席執行官總裁 | |
Tibor Keler博士 | | |
64
|
| | 總裁常務副主任兼首席科學官 | |
薩拉·卡瓦諾 | | |
48
|
| | 高級副總裁,企業事務與行政 | |
伊麗莎白·克勞利 | | |
51
|
| | 高級副總裁和首席產品開發官 | |
Margo Heath-Chiozzi醫學博士 | | |
66
|
| | 高級副總裁,監管事務 | |
弗雷迪·希門尼斯 | | |
54
|
| | 高級副總裁與總法律顧問 | |
薩姆·馬丁 | | |
52
|
| | 首席財務官兼祕書高級副總裁 | |
羅納德·佩平,博士。 | | |
67
|
| | 高級副總裁與首席商務官 | |
理查德·賴特博士。 | | |
59
|
| | 高級副總裁與首席商務官 | |
戴安·C·楊醫學博士。 | | |
67
|
| | 首席醫療官高級副總裁 | |
個人姓名
|
| |
職位和辦公室
|
|
安東尼·S·馬魯奇 | | | 董事首席執行官總裁 | |
Tibor Keler博士 | | | 總裁常務副主任兼首席科學官 | |
Margo Heath-Chiozzi醫學博士 | | | 高級副總裁,監管事務 | |
薩姆·馬丁 | | | 首席財務官兼祕書高級副總裁 | |
戴安·C·楊醫學博士。 | | | 首席醫療官高級副總裁 | |
| 阿拉科斯 | | | ITeos治療公司 | |
| Atara生物治療學 | | | Kiniksa製藥公司 | |
| C4治療學 | | | 形態 | |
| 細胞動力學 | | | 主人公治療公司 | |
| 德納利治療公司 | | | Sangamo治療公司 | |
| 埃南塔製藥公司 | | | 塞雷斯治療公司 | |
| 埃拉斯卡 | | | SpringWorks治療公司 | |
| 免疫生物 | | | Syndax製藥公司 | |
| Inovio製藥公司 | | | VIR生物技術 | |
| 愛萬斯生物治療學 | | | Zentaris製藥公司 | |
| | |
年薪
|
| | | | | | | | | | | | | |||||||||
名字
|
| |
截至2013年12月31日
2022 |
| |
截至2013年12月31日
2021 |
| |
增加
$ |
| |
增加
% |
| ||||||||||||
安東尼·S·馬魯奇
|
| | | $ | 708,144 | | | | | $ | 680,908 | | | | | $ | 27,236 | | | | | | 4.0% | | |
Tibor Keler博士
|
| | | $ | 500,573 | | | | | $ | 483,645 | | | | | $ | 16,928 | | | | | | 3.5% | | |
Margo Heath-Chiozzi醫學博士
|
| | | $ | 432,278 | | | | | $ | 417,660 | | | | | $ | 14,618 | | | | | | 3.5% | | |
薩姆·馬丁
|
| | | $ | 439,654 | | | | | $ | 412,820 | | | | | $ | 26,834 | | | | | | 6.5% | | |
戴安·C·楊醫學博士。
|
| | | $ | 453,476 | | | | | $ | 438,141 | | | | | $ | 15,335 | | | | | | 3.5% | | |
2022年企業目標
|
| |
相對
重量 |
| |
2022
成就 |
| ||||||
管道開發:
|
| | | | 75 | | | | | | 100% | | |
CDX-0159 | | | | | | | | | | | | | |
•
在醫學會議上報告慢性蕁麻疹(CSU和Cindu)1b期臨牀計劃的結果
|
| | | | | | | | | | | | |
•
完成第1b階段PN學習的註冊
|
| | | | | | | | | | | | |
•
提供第一階段高壓SC試驗的最終結果
|
| | | | | | | | | | | | |
•
在CSU和Cindu啟動第2階段試驗
|
| | | | | | | | | | | | |
•
選擇並啟動第四適應症的臨牀試驗
|
| | | | | | | | | | | | |
•
提供中期和最終的慢性毒理學結果
|
| | | | | | | | | | | | |
•
確定並實施兒科發展戰略
|
| | | | | | | | | | | | |
•
管理CMO活動以實現成功的技術轉讓和流程優化
|
| | | | | | | | | | | | |
•
生產額外的CDX-0159,以確保提供適當數量的CDX-0159支持臨牀計劃
|
| | | | | | | | | | | | |
•
為CSU、Cindu和PN開發患者行程模型
|
| | | | | | | | | | | | |
免疫炎症組合:臨牀前組合 | | | | | | | | | | | | | |
•
抗SCF方案的完整表徵和POC研究
|
| | | | | | | | | | | | |
•
適當地啟動製造活動
|
| | | | | | | | | | | | |
•
更多靶標/抗體的進展活動和評價
|
| | | | | | | | | | | | |
CDX-1140 | | | | | | | | | | | | | |
•
與pbro相結合交付結果,以支持進行/不進行決策並定義未來發展戰略
|
| | | | | | | | | | | | |
•
履行橋樑撥款承諾,包括監督CDX-1140的外部臨牀開發和製造(如果有保證)
|
| | | | | | | | | | | | |
2022年企業目標
|
| |
相對
重量 |
| |
2022
成就 |
| ||||||
CDX-527 | | | | | | | | | | | | | |
•
在CDX-527第一階段試驗中提供腫瘤定向擴展隊列的結果,以支持進行/不進行決策並定義未來發展戰略
|
| | | | | | | | | | | | |
CDX-585 | | | | | | | | | | | | | |
•
執行IND支持活動,包括CMC和毒理學,以支持IND提交
|
| | | | | | | | | | | | |
腫瘤學投資組合:臨牀前投資組合 | | | | | | | | | | | | | |
•
通過臨牀前測試支持潛在的臨牀組合
|
| | | | | | | | | | | | |
•
評估感興趣的優先目標
|
| | | | | | | | | | | | |
商業和金融運營:
|
| | | | 25 | | | | | | 100% | | |
•
根據當前的現金消耗假設,到2025年保持現金跑道
|
| | | | | | | | | | | | |
•
保持85%以上的機構所有權,重點發展我們與長期驅動的、專注於醫療保健的基金的關係
|
| | | | | | | | | | | | |
•
實施計劃以提高對肥大細胞引起的疾病和細胞科學的認識,以支持企業品牌和臨牀試驗計劃
|
| | | | | | | | | | | | |
•
執行DE&I計劃,重點是在Celldex廣泛促進包容性和多樣性,並探索確保我們的行業擁有強大和多樣化的人才渠道的方法
|
| | | | | | | | | | | | |
•
鋭化戰略招聘計劃,重點招聘與Celldex文化相融合的頂級人才
|
| | | | | | | | | | | | |
•
轉向適用於內部/外部許可、協作或併購交易的條款説明書
|
| | | | | | | | | | | | |
總計:
|
| | | | 100 | | | | | | 100% | | |
|
名字
|
| |
目標百分比
|
| |
最終支付百分比
|
| |
最終
支出 $ |
| |||||||||
安東尼·S·馬魯奇
|
| | | | 60% | | | | | | 60.0% | | | | | $ | 424,886 | | |
Tibor Keler博士
|
| | | | 45% | | | | | | 47.7% | | | | | $ | 238,773 | | |
Margo Heath-Chiozzi,醫學博士
|
| | | | 40% | | | | | | 42.4% | | | | | $ | 183,286 | | |
薩姆·馬丁
|
| | | | 40% | | | | | | 41.6% | | | | | $ | 182,896 | | |
戴安·C·楊醫學博士。
|
| | | | 40% | | | | | | 42.4% | | | | | $ | 192,274 | | |
名字
|
| |
數量:
選項 |
| |
行使價
($/Sh)(1) |
| |
授予日期
公允價值 選項獎 ($)(2) |
| |||||||||
安東尼·S·馬魯奇
|
| | | | 250,000 | | | | | | 22.48 | | | | | | 4,262,250 | | |
Tibor Keler博士
|
| | | | 91,000 | | | | | | 22.48 | | | | | | 1,551,459 | | |
Margo Heath-Chiozzi,醫學博士
|
| | | | 77,000 | | | | | | 22.48 | | | | | | 1,312,773 | | |
薩姆·馬丁
|
| | | | 85,000 | | | | | | 22.48 | | | | | | 1,449,165 | | |
戴安·楊醫學博士
|
| | | | 76,000 | | | | | | 22.48 | | | | | | 1,295,724 | | |
水平
|
| |
最低要求
股權級別 |
|
首席執行官
|
| |
年基本工資的3倍
|
|
其他行政主任
|
| |
年基本工資的1倍
|
|
名稱和主要職位
|
| |
年份
|
| |
工資
($) |
| |
獎金
($)(1) |
| |
庫存
獎項 ($) |
| |
選項
獎項 ($)(2) |
| |
非股權
獎勵 計劃 薪酬 ($) |
| |
在
中更改
養老金 值和 不合格 延期 薪酬 收入 ($) |
| |
所有其他
薪酬 ($)(3) |
| |
合計
($) |
| |||||||||||||||||||||||||||
安東尼·S·馬魯奇
總裁和科長 執行主任 |
| | | | 2022 | | | | | | 693,479 | | | | | | 424,886 | | | | | | — | | | | | | 4,262,250 | | | | | | — | | | | | | — | | | | | | 20,668 | | | | | | 5,401,283 | | |
| | | 2021 | | | | | | 668,509 | | | | | | 490,254 | | | | | | — | | | | | | 4,868,797 | | | | | | — | | | | | | — | | | | | | 18,334 | | | | | | 6,045,894 | | | ||
| | | 2020 | | | | | | 644,257 | | | | | | 395,000 | | | | | | — | | | | | | 1,950,788 | | | | | | — | | | | | | — | | | | | | 16,623 | | | | | | 3,006,668 | | | ||
Tibor Keler博士
執行副總裁 總裁和首席科學官 |
| | | | 2022 | | | | | | 491,458 | | | | | | 238,773 | | | | | | — | | | | | | 1,551,459 | | | | | | — | | | | | | — | | | | | | 8,796 | | | | | | 2,290,486 | | |
| | | 2021 | | | | | | 475,030 | | | | | | 265,000 | | | | | | — | | | | | | 1,977,949 | | | | | | — | | | | | | — | | | | | | 8,483 | | | | | | 2,726,462 | | | ||
| | | 2020 | | | | | | 457,405 | | | | | | 190,000 | | | | | | — | | | | | | 859,939 | | | | | | — | | | | | | — | | | | | | 7,508 | | | | | | 1,514,852 | | | ||
Margo Heath-Chiozzi醫學博士
高級副總裁,監管事務 |
| | | | 2022 | | | | | | 424,406 | | | | | | 183,286 | | | | | | — | | | | | | 1,312,773 | | | | | | — | | | | | | — | | | | | | 6,433 | | | | | | 1,926,898 | | |
| | | 2021 | | | | | | 409,274 | | | | | | 210,000 | | | | | | — | | | | | | 1,358,481 | | | | | | — | | | | | | — | | | | | | 6,232 | | | | | | 1,983,987 | | | ||
| | | 2020 | | | | | | 393,558 | | | | | | 149,000 | | | | | | — | | | | | | 668,842 | | | | | | — | | | | | | — | | | | | | 6,203 | | | | | | 1,217,603 | | | ||
薩姆·馬丁
高級副總裁 和首席財務官 |
| | | | 2022 | | | | | | 425,205 | | | | | | 182,896 | | | | | | — | | | | | | 1,449,165 | | | | | | — | | | | | | — | | | | | | 9,155 | | | | | | 2,066,421 | | |
| | | 2021 | | | | | | 405,303 | | | | | | 205,000 | | | | | | — | | | | | | 1,847,535 | | | | | | — | | | | | | — | | | | | | 9,044 | | | | | | 2,466,882 | | | ||
| | | 2020 | | | | | | 391,397 | | | | | | 142,000 | | | | | | — | | | | | | 840,829 | | | | | | — | | | | | | — | | | | | | 8,671 | | | | | | 1,382,897 | | | ||
戴安·C·楊醫學博士。
高級副總裁, 首席醫療官 |
| | | | 2022 | | | | | | 445,219 | | | | | | 192,274 | | | | | | — | | | | | | 1,295,724 | | | | | | — | | | | | | — | | | | | | 6,004 | | | | | | 1,939,221 | | |
| | | 2021 | | | | | | 430,163 | | | | | | 200,000 | | | | | | — | | | | | | 1,564,970 | | | | | | — | | | | | | — | | | | | | 5,834 | | | | | | 2,200,967 | | | ||
| | | 2020 | | | | | | 415,128 | | | | | | 140,000 | | | | | | — | | | | | | 573,293 | | | | | | — | | | | | | — | | | | | | 5,584 | | | | | | 1,134,005 | | |
名字
|
| |
贈款
日期 |
| |
預計未來
項下的支出 股權激勵計劃和獎勵 |
| |
所有其他
庫存 獎項: 數量: 股票數量: 庫存或單位 (#) |
| |
所有其他
選項 獎項: 數量: 證券 基礎選項 (#) |
| |
鍛鍊或
基本價格為 選項獎 ($/Sh)(1) |
| |
授予日期
公允價值 庫存和 選項獎 ($)(2) |
| ||||||||||||||||||
|
閾值
(#) |
| |
目標
(#) |
| |
最大值
(#) |
| |||||||||||||||||||||||||||||
安東尼·S·馬魯奇
|
| | | | 6/16/22 | | | | | | | | | | | | | | | | | | 250,000 | | | | | | 22.48 | | | | | | 4,262,250 | | |
Tibor Keler博士
|
| | | | 6/16/22 | | | | | | | | | | | | | | | | | | 91,000 | | | | | | 22.48 | | | | | | 1,551,459 | | |
Margo Heath-Chiozzi,醫學博士
|
| | | | 6/16/22 | | | | | | | | | | | | | | | | | | 77,000 | | | | | | 22.48 | | | | | | 1,312,773 | | |
薩姆·馬丁
|
| | | | 6/16/22 | | | | | | | | | | | | | | | | | | 85,000 | | | | | | 22.48 | | | | | | 1,449,165 | | |
戴安·楊醫學博士
|
| | | | 6/16/22 | | | | | | | | | | | | | | | | | | 76,000 | | | | | | 22.48 | | | | | | 1,295,724 | | |
| | |
期權大獎
|
| |
股票大獎
|
| |||||||||||||||||||||||||||||||||
名字
|
| |
數量:
證券 底層 未練習 選項(#) 可行使 |
| |
數量:
證券 底層 未練習 選項(#) 不可執行 |
| |
股權
獎勵 計劃 獎項: 數量: 證券 底層 未練習 未賺到的 選項 (#) |
| |
選項
練習 價格(美元) |
| |
選項
過期 日期 |
| |
數量:
個股票或 單位: 庫存 那個 沒有 已授予(#) |
| |
市場
值為 個股票或 單位: 庫存 那個 沒有 已授予($) |
| |
股權
獎勵 計劃 獎項: 數量: 未賺到的 個共享, 個單位或 其他 權利 那個 沒有 已授予(#) |
| |
股權
獎勵 計劃 獎項: 市場或 支出 值為 未賺到的 個共享, 個單位或 其他 權利 那個 沒有 已授予(#) |
| ||||||||||||
安東尼·S·馬魯奇(1)
|
| | | | — | | | | | | 250,000 | | | | | | | | | 22.48 | | | | | | 6/16/32 | | | | | | | | | | | | | | |
安東尼·S·馬魯奇(1)
|
| | | | 84,000 | | | | | | 140,000 | | | | | | | | | 28.00 | | | | | | 6/17/31 | | | | | | | | | | | | | | |
安東尼·S·馬魯奇(1)
|
| | | | 153,125 | | | | | | 91,875 | | | | | | | | | 10.38 | | | | | | 6/18/30 | | | | | | | | | | | | | | |
安東尼·S·馬魯奇(1)
|
| | | | 12,500 | | | | | | 12,500 | | | | | | | | | 2.78 | | | | | | 6/19/29 | | | | | | | | | | | | | | |
安東尼·S·馬魯奇
|
| | | | 26,665 | | | | | | — | | | | | | | | | 9.02 | | | | | | 6/13/28 | | | | | | | | | | | | | | |
安東尼·S·馬魯奇
|
| | | | 31,665 | | | | | | — | | | | | | | | | 34.80 | | | | | | 6/15/27 | | | | | | | | | | | | | | |
安東尼·S·馬魯奇
|
| | | | 31,665 | | | | | | — | | | | | | | | | 70.80 | | | | | | 6/8/26 | | | | | | | | | | | | | | |
安東尼·S·馬魯奇
|
| | | | 18,666 | | | | | | — | | | | | | | | | 381.15 | | | | | | 6/10/25 | | | | | | | | | | | | | | |
安東尼·S·馬魯奇
|
| | | | 18,666 | | | | | | — | | | | | | | | | 201.75 | | | | | | 6/4/24 | | | | | | | | | | | | | | |
安東尼·S·馬魯奇
|
| | | | 18,666 | | | | | | — | | | | | | | | | 245.40 | | | | | | 7/1/23 | | | | | | | | | | | | | | |
Tibor Keler博士(1)
|
| | | | — | | | | | | 91,000 | | | | | | | | | 22.48 | | | | | | 6/16/32 | | | | | | | | | | | | | | |
Tibor Keler博士(1)
|
| | | | 34,125 | | | | | | 56,875 | | | | | | | | | 28.00 | | | | | | 6/17/31 | | | | | | | | | | | | | | |
| | |
期權大獎
|
| |
股票大獎
|
| |||||||||||||||||||||||||||||||||
名字
|
| |
數量:
證券 底層 未練習 選項(#) 可行使 |
| |
數量:
證券 底層 未練習 選項(#) 不可執行 |
| |
股權
獎勵 計劃 獎項: 數量: 證券 底層 未練習 未賺到的 選項 (#) |
| |
選項
練習 價格(美元) |
| |
選項
過期 日期 |
| |
數量:
個股票或 單位: 庫存 那個 沒有 已授予(#) |
| |
市場
值為 個股票或 單位: 庫存 那個 沒有 已授予($) |
| |
股權
獎勵 計劃 獎項: 數量: 未賺到的 個共享, 個單位或 其他 權利 那個 沒有 已授予(#) |
| |
股權
獎勵 計劃 獎項: 市場或 支出 值為 未賺到的 個共享, 個單位或 其他 權利 那個 沒有 已授予(#) |
| ||||||||||||
Tibor Keler博士(1)
|
| | | | 67,500 | | | | | | 40,500 | | | | | | | | | 10.38 | | | | | | 6/18/30 | | | | | | | | | | | | | | |
Tibor Keler博士(1)
|
| | | | 35,640 | | | | | | 7,500 | | | | | | | | | 2.78 | | | | | | 6/19/29 | | | | | | | | | | | | | | |
Tibor Keler博士
|
| | | | 25,999 | | | | | | — | | | | | | | | | 9.02 | | | | | | 6/13/28 | | | | | | | | | | | | | | |
Tibor Keler博士
|
| | | | 10,799 | | | | | | — | | | | | | | | | 34.80 | | | | | | 6/15/27 | | | | | | | | | | | | | | |
Tibor Keler博士
|
| | | | 10,799 | | | | | | — | | | | | | | | | 70.80 | | | | | | 6/8/26 | | | | | | | | | | | | | | |
Tibor Keler博士
|
| | | | 7,766 | | | | | | — | | | | | | | | | 381.15 | | | | | | 6/10/25 | | | | | | | | | | | | | | |
Tibor Keler博士
|
| | | | 7,766 | | | | | | — | | | | | | | | | 201.75 | | | | | | 6/4/24 | | | | | | | | | | | | | | |
Tibor Keler博士
|
| | | | 7,666 | | | | | | — | | | | | | | | | 245.40 | | | | | | 7/1/23 | | | | | | | | | | | | | | |
Margo Heath-Chiozzi,醫學博士(1)
|
| | | | — | | | | | | 77,000 | | | | | | | | | 22.48 | | | | | | 6/16/32 | | | | | | | | | | | | | | |
Margo Heath-Chiozzi,醫學博士(1)
|
| | | | 23,437 | | | | | | 39,063 | | | | | | | | | 28.00 | | | | | | 6/17/31 | | | | | | | | | | | | | | |
Margo Heath-Chiozzi,醫學博士(1)
|
| | | | 52,500 | | | | | | 31,500 | | | | | | | | | 10.38 | | | | | | 6/18/30 | | | | | | | | | | | | | | |
Margo Heath-Chiozzi,醫學博士(1)
|
| | | | 36,425 | | | | | | 5,375 | | | | | | | | | 2.78 | | | | | | 6/19/29 | | | | | | | | | | | | | | |
Margo Heath-Chiozzi,醫學博士
|
| | | | 8,332 | | | | | | — | | | | | | | | | 9.02 | | | | | | 6/13/28 | | | | | | | | | | | | | | |
Margo Heath-Chiozzi,醫學博士
|
| | | | 5,000 | | | | | | — | | | | | | | | | 45.15 | | | | | | 10/3/27 | | | | | | | | | | | | | | |
薩姆·馬丁(1)
|
| | | | — | | | | | | 85,000 | | | | | | | | | 22.48 | | | | | | 6/16/32 | | | | | | | | | | | | | | |
薩姆·馬丁(1)
|
| | | | 31,875 | | | | | | 53,125 | | | | | | | | | 28.00 | | | | | | 6/17/31 | | | | | | | | | | | | | | |
薩姆·馬丁(1)
|
| | | | 66,000 | | | | | | 39,600 | | | | | | | | | 10.38 | | | | | | 6/18/30 | | | | | | | | | | | | | | |
薩姆·馬丁(1)
|
| | | | 5,375 | | | | | | 5,375 | | | | | | | | | 2.78 | | | | | | 6/19/29 | | | | | | | | | | | | | | |
薩姆·馬丁
|
| | | | 3,201 | | | | | | — | | | | | | | | | 9.02 | | | | | | 6/13/28 | | | | | | | | | | | | | | |
薩姆·馬丁
|
| | | | 4,332 | | | | | | — | | | | | | | | | 34.80 | | | | | | 6/15/27 | | | | | | | | | | | | | | |
薩姆·馬丁
|
| | | | 1,399 | | | | | | — | | | | | | | | | 70.80 | | | | | | 6/8/26 | | | | | | | | | | | | | | |
薩姆·馬丁
|
| | | | 1,399 | | | | | | — | | | | | | | | | 381.15 | | | | | | 6/10/25 | | | | | | | | | | | | | | |
薩姆·馬丁
|
| | | | 799 | | | | | | — | | | | | | | | | 201.75 | | | | | | 6/4/24 | | | | | | | | | | | | | | |
薩姆·馬丁
|
| | | | 500 | | | | | | — | | | | | | | | | 245.40 | | | | | | 7/1/23 | | | | | | | | | | | | | | |
戴安·楊,醫學博士(1)
|
| | | | — | | | | | | 76,000 | | | | | | | | | 22.48 | | | | | | 6/16/32 | | | | | | | | | | | | | | |
戴安·楊,醫學博士(1)
|
| | | | 27,000 | | | | | | 45,000 | | | | | | | | | 28.00 | | | | | | 6/17/31 | | | | | | | | | | | | | | |
戴安·楊,醫學博士(1)
|
| | | | 21,400 | | | | | | 27,000 | | | | | | | | | 10.38 | | | | | | 6/18/30 | | | | | | | | | | | | | | |
戴安·楊,醫學博士(1)
|
| | | | 3,750 | | | | | | 11,250 | | | | | | | | | 2.71 | | | | | | 7/8/29 | | | | | | | | | | | | | | |
| | |
期權大獎
|
| |
股票大獎
|
| ||||||||||||||||||
名字
|
| |
股份數量
收購日期: 練習 (#) |
| |
實現的價值
練習 ($)(1) |
| |
股份數量
收購日期: 歸屬 (#) |
| |
實現的價值
關於歸屬問題 ($) |
| ||||||||||||
安東尼·S·馬魯奇
|
| | | | 120,000 | | | | | | 3,905,158 | | | | | | — | | | | | | — | | |
Tibor Keler博士
|
| | | | 16,860 | | | | | | 575,740 | | | | | | — | | | | | | — | | |
Margo Heath-Chiozzi,醫學博士
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
薩姆·馬丁
|
| | | | 20,000 | | | | | | 634,899 | | | | | | — | | | | | | — | | |
戴安·楊醫學博士
|
| | | | 64,000 | | | | | | 2,042,396 | | | | | | — | | | | | | — | | |
終止合同時的高管福利和付款
|
| |
自願
辭職 沒有用 原因 |
| |
自願
辭職 永遠做好 原因(1) |
| |
終止
由Celldex製作 沒有 原因(1) |
| |
終止
由Celldex製作 原因 |
| |
自願終止
由高管執行 有充分的理由 或由 終止 不帶Celldex的 連接中的原因 帶有或緊隨其後的 控制權變更(2) |
| |||||||||||||||
安東尼·S·馬魯奇 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
基本工資
|
| | | $ | — | | | | | $ | 1,416,288 | | | | | $ | 1,416,288 | | | | | $ | — | | | | | $ | 1,416,288 | | |
獎金
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 980,508 | | |
股權獎勵加速(3)
|
| | | | — | | | | | | 2,876,471 | | | | | | 2,876,471 | | | | | | — | | | | | | 11,505,881 | | |
延續健康福利
|
| | | | — | | | | | | 40,320 | | | | | | 40,320 | | | | | | — | | | | | | 40,320 | | |
總計
|
| | | $ | — | | | | | $ | 4,333,079 | | | | | $ | 4,333,079 | | | | | $ | — | | | | | $ | 13,942,997 | | |
Tibor Keler博士 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
基本工資
|
| | | $ | — | | | | | $ | 500,573 | | | | | $ | 500,573 | | | | | $ | — | | | | | $ | 1,001,146 | | |
獎金
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 397,500 | | |
股權獎勵加速(3)
|
| | | | — | | | | | | 1,162,683 | | | | | | 1,162,683 | | | | | | — | | | | | | 4,650,729 | | |
延續健康福利
|
| | | | — | | | | | | 29,790 | | | | | | 29,790 | | | | | | — | | | | | | 29,790 | | |
總計
|
| | | $ | — | | | | | $ | 1,693,046 | | | | | $ | 1,693,046 | | | | | $ | — | | | | | $ | 6,079,165 | | |
Margo Heath-Chiozzi,醫學博士 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
基本工資
|
| | | $ | — | | | | | $ | 432,278 | | | | | $ | 432,278 | | | | | $ | — | | | | | $ | 864,556 | | |
獎金
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 315,000 | | |
股權獎勵加速(3)
|
| | | | — | | | | | | 912,453 | | | | | | 912,453 | | | | | | — | | | | | | 3,649,810 | | |
延續健康福利
|
| | | | — | | | | | | 29,790 | | | | | | 29,790 | | | | | | — | | | | | | 29,790 | | |
總計
|
| | | $ | — | | | | | $ | 1,374,521 | | | | | $ | 1,374,521 | | | | | $ | — | | | | | $ | 4,859,156 | | |
薩姆·馬丁 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
基本工資
|
| | | $ | — | | | | | $ | 439,654 | | | | | $ | 439,654 | | | | | $ | — | | | | | $ | 879,308 | | |
獎金
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 307,500 | | |
股權獎勵加速(3)
|
| | | | — | | | | | | 1,084,119 | | | | | | 1,084,119 | | | | | | — | | | | | | 4,336,476 | | |
延續健康福利
|
| | | | — | | | | | | 40,320 | | | | | | 40,320 | | | | | | — | | | | | | 40,320 | | |
總計
|
| | | $ | — | | | | | $ | 1,564,093 | | | | | $ | 1,564,093 | | | | | $ | — | | | | | $ | 5,563,604 | | |
終止合同時的高管福利和付款
|
| |
自願
辭職 沒有用 原因 |
| |
自願
辭職 永遠做好 原因(1) |
| |
終止
由Celldex製作 沒有 原因(1) |
| |
終止
由Celldex製作 原因 |
| |
自願終止
由高管執行 有充分的理由 或由 終止 不帶Celldex的 連接中的原因 帶有或緊隨其後的 控制權變更(2) |
| |||||||||||||||
戴安·楊醫學博士 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
基本工資
|
| | | $ | — | | | | | $ | 453,476 | | | | | $ | 453,476 | | | | | $ | — | | | | | $ | 906,952 | | |
獎金
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 300,000 | | |
股權獎勵加速(3)
|
| | | | — | | | | | | 954,637 | | | | | | 954,637 | | | | | | — | | | | | | 3,818,545 | | |
延續健康福利
|
| | | | — | | | | | | 13,410 | | | | | | 13,410 | | | | | | — | | | | | | 13,410 | | |
總計
|
| | | $ | — | | | | | $ | 1,421,523 | | | | | $ | 1,421,523 | | | | | $ | — | | | | | $ | 5,038,907 | | |
|
計劃和類別
|
| |
(a)
待發行證券數量 行權後簽發 未完成的選項和 權利(1) |
| |
(b)
加權平均鍛鍊 未償還價格 選項和權利 |
| |
(c)
證券數量 剩餘時間為 未來股權項下發行 薪酬計劃 (不包括證券 反映在(A)欄中) |
| |||||||||
證券持有人批准的股權補償計劃(2)
|
| | | | 5,085,662(3) | | | | | $ | 29.26 | | | | | | 2,014,200(4) | | |
(a) | | | (b) | | | (c) | | | (d) | | | (e) | | | (f) | | | (g) | | | (h) | | | (i) | | ||||||||||||||||||||||||
財政年度結束 12月31日, | | | 摘要 補償 表合計 聚氧乙烯 | | | 補償 實際上 支付給PEO(2) | | | 平均摘要 補償 表合計 非近地軌道近地天體(1) | | | 平均值 補償 實際支付給 非近地軌道近地天體(2) | | | 初始值 固定$100 以投資為主 關於道達爾 股東 返回 | | | 初始值 固定$100 以投資為主 論同輩羣體 總股東數 返回(3) | | | 淨虧損(In 數千人) | | | 投資餘額 (單位:千)(4) | | ||||||||||||||||||||||||
2022 | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | ( | | | | | $ | | | |||||||
2021 | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | ( | | | | | $ | | | |||||||
2020 | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | | | | | $ | ( | | | | | $ | | |
| | | 調整 | | |||||||||||||||||||||||||||||||||
| | | 摘要 補償 表合計 | | | 少於:授予日期 的公允價值 期權大獎 在此期間授予 本財政年度(a) | | | 地址:年終交易會 卓越的價值 和非既得選擇權 授予的獎項 在財政年度內(b) | | | 根據變化進行調整 的公允價值 傑出的和 非既得性期權 獲獎時間: 上一財政年度(b) | | | 根據變化進行調整 期權公允價值 獲獎時間: 上一財政年度 在此期間歸屬的 本財政年度(b) | | | 補償 實際支付 | | ||||||||||||||||||
聚氧乙烯 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
2022 | | | | $ | | | | | | ( | | | | | | | | | | | | | | | | ( | | | | | $ | | | ||||
2021 | | | | $ | | | | | | ( | | | | | | | | | | | | | | | | | | | | $ | | | |||||
2020 | | | | $ | | | | | | ( | | | | | | | | | | | | | | | | | | | | $ | | | |||||
非近地軌道平均近地天體 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
2022 | | | | $ | | | | | | ( | | | | | | | | | | | | | | | | ( | | | | | $ | | | ||||
2021 | | | | $ | | | | | | ( | | | | | | | | | | | | | | | | | | | | $ | | | |||||
2020 | | | | $ | | | | | | ( | | | | | | | | | | | | | | | | | | | | $ | | |
名字
|
| |
費用
掙得或 現金支付 ($) |
| |
庫存
獎項 ($) |
| |
選項
獎項 ($)(1) |
| |
非股權
獎勵計劃 薪酬 ($) |
| |
在
中更改
養老金 值和 不合格 延期 薪酬 收入 |
| |
所有其他
薪酬 ($) |
| |
合計
($) |
| |||||||||||||||||||||
凱倫·L·肖斯
|
| | | | 76,979 | | | | | | — | | | | | | 231,866 | | | | | | — | | | | | | — | | | | | | — | | | | | | 308,845 | | |
基思·L·布朗利
|
| | | | 61,979 | | | | | | — | | | | | | 231,866 | | | | | | — | | | | | | — | | | | | | — | | | | | | 293,845 | | |
謝麗爾·L·科恩(2)
|
| | | | 39,505 | | | | | | — | | | | | | 463,733 | | | | | | — | | | | | | — | | | | | | — | | | | | | 503,238 | | |
赫伯特·J·康拉德
|
| | | | 53,505 | | | | | | — | | | | | | 231,866 | | | | | | — | | | | | | — | | | | | | — | | | | | | 285,371 | | |
詹姆斯·J·馬裏諾
|
| | | | 65,816 | | | | | | — | | | | | | 231,866 | | | | | | — | | | | | | — | | | | | | — | | | | | | 297,682 | | |
加里·A·尼爾醫學博士。(2)
|
| | | | 34,185 | | | | | | — | | | | | | 463,733 | | | | | | — | | | | | | — | | | | | | — | | | | | | 497,918 | | |
小哈里·H·彭納
|
| | | | 58,679 | | | | | | — | | | | | | 231,866 | | | | | | — | | | | | | — | | | | | | — | | | | | | 290,545 | | |
實益擁有人姓名或名稱及營業地址*
|
| |
金額和性質
受益所有權(1) |
| |
百分比:
普通股(2) |
| ||||||
5%持有者
|
| | | | | | | | | | | | |
FMR有限責任公司
夏日大街245號 馬薩諸塞州波士頓,郵編:02210 |
| | |
|
7,064,974(3)
|
| | | |
|
15.0%
|
| |
惠靈頓管理集團有限責任公司
國會街280號 馬薩諸塞州波士頓,郵編:02210 |
| | |
|
4,647,912(4)
|
| | | |
|
9.8%
|
| |
貝萊德股份有限公司
東55號52發送街道 紐約,NY 10055 |
| | |
|
3,224,716(5)
|
| | | |
|
6.8%
|
| |
RTW投資公司,LP
40 10這是大道7樓 7這是Floor New York,NY 10014 |
| | |
|
3,084,215(6)
|
| | | |
|
6.5%
|
| |
先鋒集團
先鋒大道100號 賓夕法尼亞州馬爾文,郵編19355 |
| | |
|
2,513,564(7)
|
| | | |
|
5.3%
|
| |
董事被提名和被任命的高管
|
| | | | | | | | | | | | |
基思·L·布朗利
|
| | |
|
34,165(8)
|
| | | |
|
**
|
| |
謝麗爾·L·科恩
|
| | |
|
—
|
| | | |
|
**
|
| |
赫伯特·J·康拉德
|
| | |
|
37,481(9)
|
| | | |
|
**
|
| |
Margo Heath-Chiozzi醫學博士
|
| | |
|
149,331(10)
|
| | | |
|
**
|
| |
麗塔·I·賈恩醫學博士
|
| | |
|
—
|
| | | |
|
**
|
| |
Tibor Keler博士
|
| | |
|
231,604(11)
|
| | | |
|
**
|
| |
詹姆斯·J·馬裏諾
|
| | |
|
46,203(12)
|
| | | |
|
**
|
| |
薩姆·馬丁
|
| | |
|
153,857(13)
|
| | | |
|
**
|
| |
安東尼·S·馬魯奇
|
| | |
|
459,237(14)
|
| | | |
|
1.0%
|
| |
加里·A·尼爾醫學博士。
|
| | |
|
—
|
| | | |
|
**
|
| |
實益擁有人姓名或名稱及營業地址*
|
| |
金額和性質
受益所有權(1) |
| |
百分比:
普通股(2) |
| ||||||
小哈里·H·彭納
|
| | |
|
37,708(15)
|
| | | |
|
**
|
| |
凱倫·L·肖斯
|
| | |
|
37,703(16)
|
| | | |
|
**
|
| |
戴安·C·楊醫學博士。
|
| | |
|
115,765(17)
|
| | | |
|
**
|
| |
所有董事被提名人和高管(18人)
|
| | |
|
1,793,754(18)
|
| | | |
|
3.7%
|
| |
費用類別
|
| |
2022
|
| |
2021
|
| ||||||
| | |
(單位:千)
|
| |||||||||
審計費
|
| | | $ | 737 | | | | | $ | 653 | | |
審計相關費用
|
| | | | — | | | | | | — | | |
税費
|
| | | | — | | | | | | — | | |
所有其他費用
|
| | | | 3 | | | | | | 3 | | |
總費用
|
| | | $ | 740 | | | | | $ | 658 | | |